Published in

Taylor and Francis Group, Critical Reviews in Biochemistry and Molecular Biology, 6(42), p. 481-515, 2007

DOI: 10.1080/10409230701751611

Links

Tools

Export citation

Search in Google Scholar

Glycan Antagonists and Inhibitors: A Fount for Drug Discovery

Journal article published in 2007 by Jillian R. Brown, Brett E. Crawford, Jeffrey D. Esko
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Glycans, the carbohydrate chains of glycoproteins, proteoglycans, and glycolipids, represent a relatively unexploited area for drug development compared with other macromolecules. This review describes the major classes of glycans synthesized by animal cells, their mode of assembly, and available inhibitors for blocking their biosynthesis and function. Many of these agents have proven useful for studying the biological activities of glycans in isolated cells, during embryological development, and in physiology. Some are being used to develop drugs for treating metabolic disorders, cancer, and infection, suggesting that glycans are excellent targets for future drug development.